Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jürgen Alt"'
Autor:
Sofia Hornetz, Daniel C. Christoph, Helge Bischoff, Sebastian Michels, M Kimmich, Jürgen Alt, Monica Schäfer, Werner Spengler, Frank Griesinger, Martin Sebastian, Annette Müller, Jan Stratmann, Eckart Laack, S. Sackmann
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 144:2457-2463
Osimertinib, a third-generation irreversible mutant-selective inhibitor of EGFR kinase activity was clinically evaluated in the AURA trials, where it showed high clinical efficacy and a favorable toxicity profile in patients with acquired exon 20-EGF
Autor:
Geothy Chakupurakal, Jan Stratmann, Irene Krämer, Marius Fried, Jelena Rosentreter, Jürgen Alt
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(5)
Introduction Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suff
Autor:
Helge Bischoff, Claudia Stosnach, Wolfgang Hilbe, Alexandros Papachristofilou, Thomas Wehler, Miklos Pless, Sven D. Koch, Frank Griesinger, Tobias Seibel, Richard Cathomas, Georg Pall, Martin Früh, Ute Klinkhardt, Anke Muth, Ulrike Gnad-Vogt, Karl-Josef Kallen, Christian Weiss, Jürgen Alt, Birgit Scheel, Alfred Zippelius, Madeleine M. Hipp, Martin Sebastian, Mariola Fotin-Mleczek, Fatma Doener, Henoch S. Hong, Andreas Schröder, Michael Geißler
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Background Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulat